Texas Lawyer highlighted the success of the combination of Foley & Lardner and Gardere Wynne Sewell in the article, “Foley & Lardner Reaps Big Gains from Gardere Merger.” The article looked back on the combination on the occasion of its one-year anniversary.
The article noted that the firm saw gross revenue and net income grow as a result of the merger as well as profits per partner.
“We were delighted in the growth this year, particularly with all of the expenses associated with the consolidation and, frankly, the effort,” Foley CEO and partner Jay Rothman told Texas Lawyer.
Dallas partner Holland “Holly” O’Neil, a member of the firm’s management committee and chair of pre-merger Gardere Wynne, said the firms were well-prepared for the integration thanks to a lot of planning and meeting even before the deal closed.
The article noted that the firm saw gross revenue and net income grow as a result of the merger as well as profits per partner.
“We were delighted in the growth this year, particularly with all of the expenses associated with the consolidation and, frankly, the effort,” Foley CEO and partner Jay Rothman told Texas Lawyer.
Dallas partner Holland “Holly” O’Neil, a member of the firm’s management committee and chair of pre-merger Gardere Wynne, said the firms were well-prepared for the integration thanks to a lot of planning and meeting even before the deal closed.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”